These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 18525467)

  • 1. Prolonged survival with continuous infusion topotecan: a report of 2 cases.
    Klopfenstein KJ; Scott S; Schuller DE; Ruymann FB
    J Pediatr Hematol Oncol; 2008 Jun; 30(6):468-70. PubMed ID: 18525467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
    Ikeda M; Okusaka T; Ueno H; Takezako Y; Morizane C
    Cancer; 2005 Feb; 103(4):756-62. PubMed ID: 15637692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
    Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
    Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
    Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.
    Hütter G; Szélenyi H; Deckert PM; Keilholz U; Thiel E
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):178-84. PubMed ID: 15114411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure.
    Sirachainan N; Visudtibhan A; Tuntiyatorn L; Pakakasama S; Chuansumrit A; Hongeng S
    Pediatr Blood Cancer; 2008 Jan; 50(1):169-72. PubMed ID: 16572404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
    Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
    Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.
    Seibel NL; Krailo M; Chen Z; Healey J; Breitfeld PP; Drachtman R; Greffe B; Nachman J; Nadel H; Sato JK; Meyers PA; Reaman GH
    Cancer; 2007 Apr; 109(8):1646-53. PubMed ID: 17334983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
    Hochster HS; Plimack ER; Mandeli J; Wadler S; Runowicz C; Goldberg G; Speyer J; Wallach R; Muggia F;
    Gynecol Oncol; 2006 Feb; 100(2):324-9. PubMed ID: 16253316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports].
    Kato H; Nagano H; Ota H; Nakamura M; Wada H; Yoshioka S; Noda T; Bazarragchaa D; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Murakami T; Nakamura H; Monden M
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1842-5. PubMed ID: 16315958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of continuous local arterial-infusion chemotherapy for severely advanced hepatocellular carcinoma (HCC) using reservoir].
    Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S; Suga T; Itobayashi E; Shimauchi A
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1769-74. PubMed ID: 8397488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
    J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
    Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Problem of the long-term arterial infusion therapy with implantable reservoir for unresectable hepatocellular carcinoma].
    Kamiyama T; Nakajima Y; Sato N; Matsuoka S; Misawa K; Shimamura T; Tomioka N; Kamachi H; Une Y; Uchino J
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1576-9. PubMed ID: 1326921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
    Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
    Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
    Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic and adverse effects of topotecan combined with cisplatin for treatment of advanced squamous cell lung cancer and head and neck cancer].
    Xiang Y; Li QY; Shao JH; Yang JZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):491-3. PubMed ID: 18359722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.